在帕金森病中,血氧氧化酶-同核蛋白轴的调节失调
Marisa Cressatti1,2, Hyman M Schipper1,2
1Integrated Program in Neuroscience, McGill University, Montreal, QC H3T1E2, Canada; marisa.cressatti@mail.mcgill.ca.
NeuroSci
|November 1, 2024
概括
在帕金森病 (PD) 中血氧酶-1 (HO-1) 的上调可能通过减少miR-153和miR-223来驱动病理,增加神经毒性α-synuclein. 这些因素可能是PD的潜在治疗目标.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- 阿尔法-同核素 (α-synuclein) 聚合是帕金森病 (PD) 发病的核心.
- 血氧酶-1 (HO-1) 在PD中升高,与铁沉积和线粒体功能障碍有关.
- HO-1影响受α-synuclein影响的途径,这表明存在潜在的机械联系.
研究的目的:
- 为了探索HO-1,α-synuclein和PD之间的关系.
- 评估HO-1在调节参与α-synuclein调节的特定微RNA (miRNA) 中的作用.
- 为了确定潜在的生物标志物和治疗点为异常病理性PD.
主要方法:
- 使用了GFAP.HMOX1转基因小鼠,在星球细胞中HO-1表达升高.
- 评估了帕金森症的表型,包括尼格罗斯特里亚塔尔下和运动器官缺陷.
- 在PD患者的小鼠组织,血清和唾液中测量了α-synuclein,miR-153和miR-223的量化水平.
主要成果:
- GFAP.HMOX1小鼠表现出帕金森症表型,神经毒性S129--α-synuclein增加.
- 在GFAP.HMOX1小鼠的基底和血清中,miR-153和miR-223水平显著降低.
- 与对照组相比,在PD患者的唾液中也观察到较低的miR-153和miR-223水平.
结论:
- 上调的质HO-1通过抑制miR-153和miR-223,导致α-synuclein增加,可能会导致帕金森症.
- HO-1,特定的miRNAs和α-synuclein显示为PD的生物标志物具有前途.
- 针对HO-1/miRNA/α-synuclein轴可能为PD提供一种新的疾病修饰治疗策略.
相关概念视频
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Parkinson's Disease: Overview
483
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
483
Parkinson's Disease: Treatment
224
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
224
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K


